Back to results
US 2010/0135905 A1Published application
Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides
OwnerDennis E. Hallahaninventor
Life of this patent
Estimating the term…
Abstract
A method for assessing cancer susceptibility to molecular targeted therapy. Also provided are methods for in vivo panning of diverse molecules for isolation of targeting ligands that specifically bind an apoptotic cell associated with a responding tumor, targeting ligands identified by the panning methods, and diagnostic and imaging uses therefor.
Claims24
1-98. (canceled)
A method of assessing the effectiveness of a treatment on a target, the method comprising:
- (a) treating a tumor with at least one of ionizing radiation and an agent selected from the group consisting of a receptor inhibitor and a receptor tyrosine kinase inhibitor (TKI);
- (b) contacting the target with a peptide that binds to the target, wherein the peptide comprises any of SEQ ID NOs:
- 1-18;
- and
- (c) determining an extent of binding of the peptide to the target;
- wherein the extent of binding to the target correlates with the effectiveness of the treatment.
3 more elements
A method of noninvasive imaging of a cell undergoing apoptosis, the method comprising:
- (a) binding to a cell undergoing apoptosis a reagent that binds to a molecule induced by apoptosis, the reagent comprising:
- (i) a peptide the binds to a tumor treated with at least one of ionizing radiation and an agent selected from the group consisting of a receptor inhibitor and a receptor tyrosine kinase inhibitor (TKI), wherein the peptide comprises any of SEQ ID NOs:
- 1-18;
- and
- (ii) a contrast agent;
- and
- (b) detecting the binding of the reagent to the cell, whereby a cell undergoing apoptosis is imaged.
4 more elements
Dependencies are inferred from the claim text.